J&J wins another label expansion for Darzalex in Europe – PMLiVE

Johnson & Johnson, through its Janssen pharmaceutical division, has scored another label expansion in Europe for Darzalex in newly diagnosed multiple myeloma patients.

This time round, the newly approved formulation is comprised of anti-CD38 Darzalex (daratumumab) in combination with bortezomib, thalidomide and dexamethasone (VTd),a triple regimen which is commonly used in the treatment of multiple myeloma.

The European Commission has granted a marketing authorisation for the Darzalex-VTd combination as a treatment of newly diagnosed patients who are eligible for autologous stem cell transplant (ASCT). J&J was granted FDA approval for this Darzalex regimenlast September, in the same patient population.

The new expansion authorisation was based on results from J&Js phase 3 CASSIOPEIA trial, in which Darzalex and VTd significantly improved progression-free survival by 93% compared to 85% of those treated with VTd alone.

We asked ourselves can we improve the standard of care that is bortezomib, thalidomide and dexamethasone (VTd) to provide patients with valuable extra time? said Philippe Moreau, principal investigator and head of the haematology department at the University Hospital of Nantes, France.

The CASSIOPEIA study answered that question definitively, demonstrating that the addition of daratumumab in combination with VTd can lead to very deep remissions and also prolong PFS, he added.

The drug, which was originally developed by Danish biotech Genmab, is a monoclonal antibody (mAb) that targets the CD38 protein, which is highly expressed on multiple myeloma cells.

J&J has largely had the anti-CD38 category to itself since Darzalex was first approved in 2015, and has chalked up a number of label expansions during that time, importantly in the early stages of the disease.

This includes anothercombination regimen, with Celegenes Revlimid (lenalidomide) and dexamethasone (DRd), for the treatment of newly diagnosed multiple myeloma patients who are ineligible for ASCT.

This approval represents our commitment to investigate daratumumab in earlier disease stages of multiple myeloma and to develop more effective frontline treatment options for newly diagnosed patients who are eligible for transplantation, said Craig Tendler, vice president, clinical development and global medical affairs, oncology, Janssen Research & Development.

However, J&J could see its exclusivity disappear as Sanofis rival anti-CD38 mAb isatuximab is currently being reviewed by the FDA for the treatment of relapsed/refractory multiple myeloma with a target action date for a decision due on30 April.

J&Js expansion into the earlier settings will see it retain a large share of the market, but the encroachment of another therapy could still damage sales of the blockbuster therapy.

Originally posted here:
J&J wins another label expansion for Darzalex in Europe - PMLiVE

Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Predicted to Grow by 2028 with Competitive Situation and Business…

The research report on Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market offers the effective objectives of the market share, growth aspects, and market segmentation. In addition, the report includes the detailed analysis for significant designing of innovative strategies for service providers. Likewise, this report also provides the collection of information which is gathered for qualitative methodologies as well as survey studied by an experienced analyst. Moreover, the Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) market report includes the comprehensive details of the market comprising market trends, growth paths, market opportunities, limitations, challenges, and leading service providers of the respective market for the prediction period.

Request a sample of this report @ https://www.orbisresearch.com/contacts/request-sample/4155718

In addition, the Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) market report delivers the fundamental analysis which is carried out by experienced analysts with a perspective of the Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) industry. Furthermore, the Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) market report also covers the structures of the industries across the globe. The research report is designed with the help of proficient standardized tools such as SWOT analysis and others. Additionally, the Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) report offers a brief judgement of the global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) market. The Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) industry report offers a broad estimation of the prediction period that will guide the users to take significant decisions over the forecasted chart. This report contain the overall analysis of the Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) market.

Key Players Analysis:

JanssenQiagenAdvanced Cell DiagnosticsApoCellBiofluidicaClearbridge BiomedicsCytoTrackCelseeFluxionGilupiCynvenioOn-chipYZY BioBioViewFluidigmIkonisysAdnaGenIVDiagnosticsMiltenyi BiotecScreenCellSilicon Biosystems

Browse the complete report @ https://www.orbisresearch.com/reports/index/2013-2028-report-on-global-circulating-tumor-cells-ctcs-and-cancer-stem-cells-cscs-market-by-player-region-type-application-and-sales-channel

Market split by Type:

CellSearchOthers

Market split by Application:

Breast Cancer Diagnosis and TreatmentProstate Cancer Diagnosis and TreatmentColorectal Cancer Diagnosis and TreatmentLung Cancer Diagnosis and TreatmentOther Cancers Diagnosis and Treatment

Market segment by Region/Country including:

North America (United States, Canada and Mexico)Europe (Germany, UK, France, Italy, Russia and Spain etc.)Asia-Pacific (China, Japan, Korea, India, Australia and Southeast Asia etc.)South America Brazil, Argentina, Colombia and Chile etc.)Middle East & Africa (South Africa, Egypt, Nigeria and Saudi Arabia etc.)

Major Points from Table of Content:

Chapter 1 Market OverviewChapter 2 Market Segment Analysis by PlayerChapter 3 Market Segment Analysis by TypeChapter 4 Market Segment Analysis by ApplicationChapter 5 Market Segment Analysis by Sales ChannelChapter 6 Market Segment Analysis by RegionChapter 7 Profile of Leading PlayersChapter 8 Upstream and Downstream Analysis of Scar DressingChapter 9 Development Trend of (2019-2028)Chapter 10 Appendix

Place a purchase order of this report @ https://www.orbisresearch.com/contact/purchase-single-user/4155718

About Us:

Orbis Research (orbisresearch.com) is a single point aid for all your market research requirements. We have vast database of reports from the leading publishers and authors across the globe. We specialize in delivering customized reports as per the requirements of our clients. We have complete information about our publishers and hence are sure about the accuracy of the industries and verticals of their specialization. This helps our clients to map their needs and we produce the perfect required market research study for our clients.

Contact Us:

Hector CostelloSenior Manager Client Engagements4144N Central Expressway,Suite 600, Dallas,Texas 75204, U.S.A.Phone No.: +1 (972)-362-8199 ; +91 895 659 5155

Original post:
Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Predicted to Grow by 2028 with Competitive Situation and Business...

Mayo woman raising funds for niece, 4, who is losing her sight from three different eye conditions – Extra.ie

A Mayo woman is raising funds for her niece who is losing her sight from three different eye conditions.

Magdalena Krawiec, originally from Poland, wants to help her goddaughter Zuzia Krawiec to get the best care possible.

Zuzia, four, was born with an eye disease called congenital nystagmus, which can be caused with the eye itself or by a problem with the visual pathway from the eye to the brain.

Around four months after she was born, Zuzia was then diagnosed with hyperopia astigmatism.

The condition affects Zuzias sight so that objects close to her are out of focus.

This along with her mcular hypoplasia, which she was only diagnosed with recently, make it impossible for her to see anything in detail.

Her aunt told Extra.ie: The macular hypoplasia is the worst because theres not much we can do about it.

It affects the vision clarity and because of it she will never be able to see clearly. She can only see as far as one metre and its basically shadows and lights

Were working on her sight so that she will eventually be able to see 10 or 15 metres in front of her but thats going to be over many years.

Zuzia has to take medication and do exercises to help her eyes improve but shes also had to have surgeries.

Shes had one of ten surgeries so far and the family are looking into stem cell treatment, which more people are interested in in recent years.

The family hope to schedule her second operation soon as the masses are really loose behind her eye and they need to tighten those muslces.

This operation will held Zuzias eyeball become more steady and so help her look straight because right now theyre all over the place.

Theyre kind of shaky, Magdalena continued. Thats the problem.

Zuzia is currently in play school but once a week she goes to a special school where she does two hours of different exercises for children with disabilities.

One hour she learns how to use her hands to recognise objects and another hour Zuzia uses an optical enlarger, something her family hopes to buy her so she can see things better.

It will be able to help her see better as it makes pictures at least 50 times larger, Magdalena said.

Zuzia needs constant care, her aunt tells Extra.ie, so that she doesnt hurt herself as she walks around.

Magdalena said: She needs help going to the toilet or going outside, anything where there may be obstacles in her way.

She cant see so she could walk into a wall or something, she could hurt herself.

Zuzia will never have the same sight the average person has, but with the operations she may gain better sight.

Magdalena revealed that she and her family dont know the root of the problem and hope genetic tests will help them get an idea of what is going on.

The genetic tests have to be done through the national health service and can take two to three years, but another huge hit is the cost of the tests.

Its around 2,500, Magdalena said. Its ridiculous because shes young, we need to do it as quick as possible.

The brain is getting used to the eyes not working, so the quicker we get it fixed the better. We want her to actually see something.

Despite her eyesight, Zuzia is a happy child and a big sister to her baby brother.

However, Zuzia has started asking about her brothers sight, wondering: How come he can see and I cant?

Its heartbreaking, Magdalena admitted. Its hard to explain to her that her eyes are sick.

To help her family, Magdalena set up a GoFundMe page to raise money for Zuzias operation and her care, which you can donate to here.

Magdalena has also has a collection point in The Breadski Brothers store in Westport to help raise funds.

She really needs specialised care, especially during these early years in her development, to improve her chances of avoiding total blindness and giving her the childhood she deserves.

Read more here:
Mayo woman raising funds for niece, 4, who is losing her sight from three different eye conditions - Extra.ie

Michael Schumacher health update: Neurosurgeon claims F1 legend ‘nothing like we remember’ – Express.co.uk

The Formula One legend suffered a brain injury in December 2013 and has only just come out of an induced coma. Due to the amount of time since his injury, leading surgeon, Nicola Acciari, has warned the Formula One driver is now a different person.

The surgeon told Contro Copertina: "We must imagine a person very different from the one we remember on the track, with a very altered and deteriorated organic, muscular and skeletal structure.

"All as a result of the brain trauma he suffered."

Updates on the health of the racing legend have been kept to a minimum over the last few years.

What is known is that Michael Schumacher has been receiving groundbreaking treatment from French surgeon, Philippe Menasche.

Mr Menasche is a leading light in stem cell therapy and was reportedly using surgery to transfer cells from his heart to the brain according to Spanish publication 20minutos.

The treatment took place at the Georges-Pompidou Hospital and according to Schumacher's doctor, professor Jean-Francois Payen, he has returned this month for the same treatment.

He said: "There is a one to three-year plan for the regeneration period.

I visit Schumacher frequently and talk to his family about the progress I see.

JUST IN:Michael Schumacher latest: Fan club to mark anniversary of accident

"I saw the race together withMichael Schumacherat his home in Switzerland.

"Michael is in the best hands and is well looked after in his house.

"He does not give up and keeps fighting.

"His family is fighting just as much and of course our friendship cannot be the same as it once was just because there's no longer the same communication as before."

During his stem cell treatment, Mr Menasche was forced to defend himself over accusations he was using Schumacher as an experiment as opposed to a patient to operate on.

The professor at the University of Alabama and leader of the National Institute for Medical and Health research hit back and said: There was great attention to our department, but it has already returned to normal.

There has been great progress in the last 20 years, but the truth is that we still know little.

To mark the six-year anniversary of his injury, his wife Corinna, issued a message to his fans.

Continue reading here:
Michael Schumacher health update: Neurosurgeon claims F1 legend 'nothing like we remember' - Express.co.uk

Bone Therapeutics announces 2020 business outlook and reports year-end 2019 cash position – GlobeNewswire

Press release Regulated information

Phase III study of JTA-004 in patients with knee osteoarthritis on track to start patient enrollment early 2020

CTA submission initiated for Phase IIb with ALLOB in difficult tibial fractures

Two-year follow-up Phase IIa data for ALLOB in spinal fusion expected in H2 2020

Cash burn for the full year 2019 below guidance

Gosselies, Belgium, 22January 2020, 7am CET BONE THERAPEUTICS (Euronext Brussels and Paris: BOTHE), the leading biotech company focused on the development of innovative cell and biological therapies to address high unmet medical needs in orthopedics and bone diseases, today provides its business outlook for 2020 and reports its cash position for the year ending December31, 2019.

Outlook for 2020

Clinical Trial Application (CTA) for the knee osteoarthritis pivotal Phase III study with the Companys enriched protein solution, JTA-004, has been submitted to regulatory authorities in 5 European countries and Hong Kong Special Administrative Region, with patient enrollment expected to start early 2020. The JTA-004 PhaseIII study is a placebo and active-controlled, randomized, double-blind study to evaluate the potential of a single, intra-articular injection of JTA-004 to reduce osteoarthritic pain in the knee compared to placebo or Hylan G-F 20, the leading osteoarthritis treatment on the market. The first results of the study are anticipated in the second quarter of 2021 after afollow-up period of 3 months.

The Company is initiating the CTA submission process in Europe for a PhaseIIb clinical trial with its allogeneic bone cell therapy product, ALLOB, in patients with tibial fractures at risk for delayed healing, using its optimized production process. The first patients are expected to be enrolled in Q2 2020.

In the second half of 2020, the Company expects to report results from the 2-year follow-up period of thePhaseIIa study with ALLOB in patients undergoing a spinal fusion procedure following the successful completion of the 12-months period for which positive results were published in July 2019. These results demonstrated that ALLOB in addition to the standard of care procedure was well-tolerated and resulted in significant clinical and radiological improvements.

Miguel Forte, Chief Executive Officer of Bone Therapeutics commented: I am very pleased to see that we continue to make strong progress in executing on our business strategy to become a global innovator in bone related diseases. In the next coming months, we expect to run a pivotal trial with our novel protein solution, JTA-004, with the goal to provide relevant regulatory and clinical evidence about the potential of JTA-004 as a treatment option for the many patients suffering from knee osteoarthritic pain. The anticipated start of the PhaseIIb study in patients with difficult to heal fractures and the 24months results from the PhaseIIa trial in patients undergoing a spinal fusion procedure, which we expect later this year, could further underscore the unique potential of ALLOB to bring much needed innovation to the treatment of severe bone disorders."

Cash position for the full year ended December 31, 2019

The continued strong focus on cash management resulted in a net cash utilization of 11.5million(1) for the full year 2019 which was below the Companys guidance of 12-13million. The net cash position totaled 8.6million(1) for the year ended December 31, 2019. The Company anticipates having sufficient cash to carry out its business objectives into Q3 2020.

Following the previously announced discontinuation of the autologous cell therapy program, PREOB, end 2018, Asahi Kasei and the Company agreed to formally end the PREOB licensing agreement. As a result, Bone Therapeutics and the Walloon Region agreed to terminate the related reimbursable grant agreements under the form of Recoverable Cash Advances, thereby reducing cash reimbursements and associated interest payments that were due by the Company by 1.4M over the next 5 years.

Financial Calendar 2020

The financial calendar is communicated on an indicative basis and may be subject to change.

(1) Unaudited number

About Bone Therapeutics

Bone Therapeutics is a leading biotech company focused on the development of innovative products to address high unmet needs in orthopedics and bone diseases. The Company has a broad, diversified portfolio of bone cell therapies and an innovative biological product in later-stage clinical development, which target markets with large unmet medical needs and limited innovation.

Bone Therapeutics is developing an off-the-shelf protein solution, JTA-004, which is entering Phase III development for the treatment of pain in knee osteoarthritis. Positive Phase IIb efficacy results in patients with knee osteoarthritis showed a statistically significant improvement in pain relief compared to a leading viscosupplement. The clinical trial application (CTA) to start the pivotal Phase III program has been submitted to the regulatory authorities in Europe and the trial is expected to start in Q1 2020.

Bone Therapeutics other core technology is based on its cutting-edge allogeneic cell therapy platform (ALLOB) which can be stored at the point of use in the hospital, and uses a unique, proprietary approach to bone regeneration, which turns undifferentiated stem cells from healthy donors into bone-forming cells. These cells can be administered via a minimally invasive procedure, avoiding the need for invasive surgery, and are produced via a proprietary, scalable cutting-edge manufacturing process. Following the promising Phase IIa efficacy and safety results for ALLOB, the Company has started the CTA submission procedure with the regulatory authorities in Europe to start the Phase IIb clinical trial with ALLOB in patients with difficult-to-heal fractures, using its optimized production process.

The ALLOB platform technology has multiple applications and will continue to be evaluated in other indications including spinal fusion, osteotomy and maxillofacial and dental applications.

Bone Therapeutics cell therapy products are manufactured to the highest GMP (Good Manufacturing Practices) standards and are protected by a broad IP (Intellectual Property) portfolio covering ten patent families as well as knowhow. The Company is based in the BioPark in Gosselies, Belgium. Further information is available at http://www.bonetherapeutics.com.

Contacts

Bone Therapeutics SAMiguel Forte, MD, PhD, Chief Executive OfficerJean-Luc Vandebroek, Chief Financial OfficerTel: +32 (0) 71 12 10 00investorrelations@bonetherapeutics.com

International Media Enquiries:Consilium Strategic CommunicationsMarieke VermeerschTel: +44 (0) 20 3709 5701bonetherapeutics@consilium-comms.com

For French Media and Investor Enquiries:NewCap Investor Relations & Financial CommunicationsPierre Laurent, Louis-Victor Delouvrier and Arthur RouillTel: + 33 (0)1 44 71 94 94bone@newcap.eu

Certain statements, beliefs and opinions in this press release are forward-looking, which reflect the Company or, as appropriate, the Company directors` current expectations and projections about future events. By their nature, forward-looking statements involve a number of risks, uncertainties and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Forward looking statements contained in this press release regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. As a result, the Company expressly disclaims any obligation or undertaking to release any update or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward-looking statements are based. Neither the Company nor its advisers or representatives nor any of its subsidiary undertakings or any such person`s officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.

See original here:
Bone Therapeutics announces 2020 business outlook and reports year-end 2019 cash position - GlobeNewswire

Science Talk – Tell me more about telomeres: how ‘basic’ science can help us treat cancer – The Institute of Cancer Research

Image: Chromosomes and their telomeres (visualised in red). Credit: Thomas Ried, NCI Center for Cancer Research

You might not have heard of telomeres but theyre incredibly important they are the caps that protect the end of chromosomes. They work like the plastic tips that stop your shoelaces from fraying.

All cancers alter telomeres in order to survive, so by doing basic research to try to understand how telomere replication and processing works, Max and his team hope to identify possible new ways to target and treat cancer.

Having joined the Division of Cancer Biology in October 2019, Dr Max Douglasis now one of the newest Team Leaders at the ICR. I met him at our Chester Beatty Laboratories in Chelsea, where he told me more about his work.

Max studied for his PhD in biochemistry and cell biology at the University of Cambridge. He then joined Dr John Diffleys team in Londons Clare Hall Laboratories which later became part of the Francis Crick Institute where he focused on studying the early stages of DNA replication.

At the Crick, he helped establish in detail how a protein complex called the CMG replicative helicase that helps unwind DNA during replication, is assembled and activated.

Now at the ICR, Max leads his own research team studying DNA replication but in the context of telomeres and cancer.

My main project is to rebuild telomeres in the lab and then unpick how they work how they are replicated and how they are processed. This knowledge is generally useful, but we will focus on studying it in the context of cancer, explained Max.

Lets finish it:help us revolutionise cancer treatment. We aim to discover a new generation of cancer treatments so smart and targeted, that more patients will defeat their cancer and finish what they started.

Support our work

When a cell becomes cancerous, it divides more often and every time it divides, its telomeres become shorter and shorter. Once there is no telomere left, the DNA unravels, like a shoelace fraying, and the cell dies. This eventually happens in most healthy cells telomeres shorten over time until cell division is no longer possible, leading to cell death.

While this loss of telomere protection can cause cancer cells and healthy cells to die, it can also lead to a state of genome instability that helps cancer survive and spread.

We also know that cancer cells can escape death by making telomerase, an enzyme that prevents telomeres from getting short. Certain cells in our body, such as stem cells, are able to divide over and over again thanks to telomerase. Cancer cells take advantage of this enzyme and hijack it to maintain telomere length which enables them to continue to divide and spread.

In other words, telomeres seem to play a role in the death of cancer cells but theyre also crucial for their survival. However, the molecular steps that guide telomere replication and processing remain poorly understood.

By using genetics and replicating cellular processes in a test tube, through a technique known as reconstitution biochemistry, Max and his team hope to better understand how telomeres are processed, and how they are inherited from one generation of cells to the next.

If Max and his team can dissect how telomeres work and clarify their link to cancer, maybe well figure out new ways to treat it.

His research might seem quite distant from the clinic, but Max knows he belongs at the ICR, which has an exemplary track record in making discoveries that ultimately benefit people with cancer.

I really value the ICRs commitment to doing basic, laboratory science. Good basic science is necessary to understand cancer, and the ICR values that. Here, I can figure out how to use my findings to benefit people, and that, in turn, will also hugely benefit my work, Max said.

I feel very lucky to work at an institution with a mission, being able to do what I love while getting opportunities to make discoveries that could help people.

As a new Team Leader, Max is currently the only member of his team but a higher scientific officer will be joining this month, as well as a post-doctoral training fellow, who will be joining in March. They will also start recruiting for a PhD student. As he told me, he cant wait for the new team members to join him in January.

Im excited to supervise other people for the first time. I want to build a strong team and a good environment for them to thrive in.

See original here:
Science Talk - Tell me more about telomeres: how 'basic' science can help us treat cancer - The Institute of Cancer Research

The Clinical Trial that MS Patients Have Been Waiting For – Multiple Sclerosis News Today

People with multiple sclerosis have been waiting for this: A full-scale clinical trial testing the effectiveness of stem cell transplantation as an MS treatment. The trial is being conducted by the U.S. National Institutes of Health, and its enrolling people with MSat several centers in the United States and one in the United Kingdom.

The U.S. has been behind the curve when it comes to approving stem cell treatments for people with MS. Autologous hematopoietic stem cell transplantation (aHSCT) has been available in Mexico and Russia for several years, but isnt widely available in the U.S.

In the procedure, doctors collect a patients blood-forming stem cells, give the patient high-dose chemotherapy to deplete the immune system, and then return the patients own stem cells to rebuild the immune system. The system, hopefully, returns free of cells believed to be involved with MS.

Three years ago, following a promising aHSCT study, Dr. Anthony Fauci was optimistic but cautious. Fauci is the director of the National Institute of Allergy and Infectious Diseases. He said, These extended findings suggest that one-time treatment with HDIT/HCT may be substantially more effective than long-term treatment with the best available medications for people with a certain type of MS. But Fauci emphasized that a larger trial was still necessary. It appears that trial has finally arrived.

The Phase 3 trial, called BEAT-MS (NCT04047628), will put aHSCT head-to-head against the top-line disease-modifying therapies (DMTs) available in the U.S. to treat MS.

It will enroll 156 adults, ages 18 to 55, with a diagnosis of relapsing-remitting MS (RRMS) at 21 sites 20 in the U.S. and one in the U.K. Participants will be randomly assigned to receive either aHSCT or one of the high-efficacy MS treatments currently in use: Ocrevus (ocrelizumab), Lemtrada/Campath (alemtuzumab), Tysabri (natalizumab), or Rituxan (rituximab). The participants, who wont know which treatment theyre receiving, will be followed for six years.

In a news release, investigators said they want to compare how much time elapses between the start of the treatment and an MS relapse. Theyll also compare the newly developing immune systems of the participants who receive aHSCT with the immune systems of those who receive a DMT.

Finally, theyll compare the effects of the two treatment types on other measures of disease activity and severity, their cost-effectiveness in terms of healthcare costs and productivity, and participants quality of life. We hope that BEAT-MS will clarify the best way to treat people with relapsing MS, said Dr. Jeffrey Cohen, the trials leader.

I hope so, too. A study such as this is long overdue. But I think I echo the feelings of many people with MS when I express dismay that were probably still at least six years away from approval of aHSCT in the U.S.

As I wrote three years ago, [S]cientists have been studying stem cell treatments for years and it sure seems as if were still crawling when we should be cruising. Also, why limit this study to people with RRMS? Why not include those with primary and secondary progressive MS? Am I wrong to think that they would benefit from aHSCT as much, if not more, as those with relapsing MS?

What do you think?

Starting this month, Multiple Sclerosis News Today columnist Jennifer Powell and I have begun recording MS news and feature stories in audio format. Jennifers audio reports are available on SoundCloud every Monday, and mine are available every Thursday. Click here to give us a listen.

Youre invited to visit my personal blog at http://www.themswire.com.

***

Note: Multiple Sclerosis News Today is strictly a news and information website about the disease. It does not provide medical advice, diagnosis, or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website. The opinions expressed in this column are not those of Multiple Sclerosis News Today or its parent company, BioNews Services, and are intended to spark discussion about issues pertaining to multiple sclerosis.

Ed Tobias is a retired broadcast journalist. Most of his 40+ year career was spent as a manager with the Associated Press in Washington, DC. Tobias was diagnosed with Multiple Sclerosis in 1980 but he continued to work, full-time, meeting interesting people and traveling to interesting places, until retiring at the end of 2012.

See the article here:
The Clinical Trial that MS Patients Have Been Waiting For - Multiple Sclerosis News Today

Global Cell Therapy Technologies Market Industry Analysis And Forecast (2018-2026) Dagoretti News – Dagoretti News

obal Cell Therapy Technologies Marketwas valued US$ 12 billion in 2018 and is expected to reach US$ 35 billion by 2026, at CAGR of 12.14 %during forecast period.

The objective of the report is to present comprehensive assessment projections with a suitable set of assumptions and methodology. The report helps in understanding Global Cell Therapy Technologies Market dynamics, structure by identifying and analyzing the market segments and projecting the global market size. Further, the report also focuses on the competitive analysis of key players by product, price, financial position, growth strategies, and regional presence. To understand the market dynamics and by region, the report has covered the PEST analysis by region and key economies across the globe, which are supposed to have an impact on market in forecast period. PORTERs analysis, and SVOR analysis of the market as well as detailed SWOT analysis of key players has been done to analyze their strategies. The report will to address all questions of shareholders to prioritize the efforts and investment in the near future to the emerging segment in the Global Cell Therapy Technologies Market.

REQUEST FOR FREE SAMPLE REPORT:https://www.maximizemarketresearch.com/request-sample/31531

Global Cell Therapy Technologies Market: OverviewCell therapy is a transplantation of live human cells to replace or repair damaged tissue and/or cells. With the help of new technologies, limitless imagination, and innovative products, many different types of cells may be used as part of a therapy or treatment for different types of diseases and conditions. Celltherapy technologies plays key role in the practice of medicine such as old fashioned bone marrow transplants is replaced by Hematopoietic stem cell transplantation, capacity of cells in drug discovery. Cell therapy overlap with different therapies like, gene therapy, tissue engineering, cancer vaccines, regenerative medicine, and drug delivery. Establishment of cell banking facilities and production, storage, and characterization of cells are increasing volumetric capabilities of the cell therapy market globally. Initiation of constructive guidelines for cell therapy manufacturing and proven effectiveness of products, these are primary growth stimulants of the market.

Global Cell Therapy Technologies Market: Drivers and RestraintsThe growth of cell therapy technologies market is highly driven by, increasing demand for clinical trials on oncology-oriented cell-based therapy, demand for advanced cell therapy instruments is increasing, owing to its affordability and sustainability, government and private organization , investing more funds in cell-based research therapy for life-style diseases such as diabetes, decrease in prices of stem cell therapies are leading to increased tendency of buyers towards cell therapy, existing companies are collaborating with research institute in order to best fit into regulatory model for cell therapies.Moreover, Healthcare practitioners uses stem cells obtained from bone marrow or blood for treatment of patients with cancer, blood disorders, and immune-related disorders and Development in cell banking facilities and resultant expansion of production, storage, and characterization of cells, these factors will drive the market of cell therapy technologies during forecast period.

On the other hand, the high cost of cell-based research and some ethical issue & legally controversial, are expected to hamper market growth of Cell Therapy Technologies during the forecast period

AJune 2016, there were around 351 companies across the U.S. that were engaged in advertising unauthorized stem cell treatments at their clinics. Such clinics boosted the revenue in this market.in August 2017, the U.S. FDA announced increased enforcement of regulations and oversight of clinics involved in practicing unapproved stem cell therapies. This might hamper the revenue generation during the forecast period; nevertheless, it will allow safe and effective use of stem cell therapies.

Global Cell Therapy Technologies Market: Segmentation AnalysisOn the basis of product, the consumables segment had largest market share in 2018 and is expected to drive the cell therapy instruments market during forecast period at XX % CAGR owing to the huge demand for consumables in cell-based experiments and cancer research and increasing number of new product launches and consumables are essential for every step of cell processing. This is further expected to drive their adoption in the market. These factors will boost the market of Cell Therapy Technologies Market in upcoming years.

On the basis of process, the cell processing had largest market share in 2018 and is expected to grow at the highest CAGR during the forecast period owing to in cell processing stage,a use of cell therapy instruments and media at highest rate, mainly in culture media processing. This is a major factor will drive the market share during forecast period.

Global Cell Therapy Technologies Market: Regional AnalysisNorth America to held largest market share of the cell therapy technologies in 2018 and expected to grow at highest CAGR during forecast period owing to increasing R&D programs in the pharmaceutical and biotechnology industries. North America followed by Europe, Asia Pacific and Rest of the world (Row).

Do Inquiry Before Purchasing Report Here:https://www.maximizemarketresearch.com/inquiry-before-buying/31531

Scope of Global Cell Therapy Technologies Market

Global Cell Therapy Technologies Market, by Product

Consumables Equipment Systems & SoftwareGlobal Cell Therapy Technologies Market, by Cell Type

Human Cells Animal CellsGlobal Cell Therapy Technologies Market, by Process Stages

Cell Processing Cell Preservation, Distribution, and Handling Process Monitoring and Quality ControlGlobal Cell Therapy Technologies Market, by End Users

Life Science Research Companies Research InstitutesGlobal Cell Therapy Technologies Market, by Region

North America Europe Asia Pacific Middle East & Africa South AmericaKey players operating in the Global Cell Therapy Technologies Market

Beckman Coulter, Inc. Becton Dickinson and Company GE Healthcare Lonza Merck KGaA MiltenyiBiotec STEMCELL Technologies, Inc. Terumo BCT, Inc. Thermo Fisher Scientific, Inc. Sartorius AG

MAJOR TOC OF THE REPORT

Chapter One: Cell Therapy Technologies Market Overview

Chapter Two: Manufacturers Profiles

Chapter Three: Global Cell Therapy Technologies Market Competition, by Players

Chapter Four: Global Cell Therapy Technologies Market Size by Regions

Chapter Five: North America Cell Therapy Technologies Revenue by Countries

Chapter Six: Europe Cell Therapy Technologies Revenue by Countries

Chapter Seven: Asia-Pacific Cell Therapy Technologies Revenue by Countries

Chapter Eight: South America Cell Therapy Technologies Revenue by Countries

Chapter Nine: Middle East and Africa Revenue Cell Therapy Technologies by Countries

Chapter Ten: Global Cell Therapy Technologies Market Segment by Type

Chapter Eleven: Global Cell Therapy Technologies Market Segment by Application

Chapter Twelve: Global Cell Therapy Technologies Market Size Forecast (2019-2026)

Browse Full Report with Facts and Figures of Cell Therapy Technologies Market Report at:https://www.maximizemarketresearch.com/market-report/global-cell-therapy-technologies-market/31531/

About Us:

Maximize Market Research provides B2B and B2C market research on 20,000 high growth emerging technologies & opportunities in Chemical, Healthcare, Pharmaceuticals, Electronics & Communications, Internet of Things, Food and Beverages, Aerospace and Defense and other manufacturing sectors.

Contact info:

Name: Lumawant Godage

Organization: MAXIMIZE MARKET RESEARCH PVT. LTD.

Email: [emailprotected]

Contact: +919607065656/ +919607195908

Website: http://www.maximizemarketresearch.com

Read this article:
Global Cell Therapy Technologies Market Industry Analysis And Forecast (2018-2026) Dagoretti News - Dagoretti News

Libby Clegg health: Dancing On Ice star is registered blind – what is her condition? – Express

Libby Clegg, 29, has represented both Scotland and Great Britain at international sporting events. She won a silver medal at the 2008 Summer Paralympics and won gold at the 2016 Paralympic Games. Clearly up for any challenge, the sprinter is now competing in ITVs Dancing On Ice.

But why exactly is the star registered as blind? The sporting star has a deteriorating eye condition known as Stargardts Macular Dystrophy which gives her only slight peripheral vision in her left eye.

Libby has described her eyesight as being like looking at a pixelated computer screen or a scrunched-up firework, when speaking to The Daily mail.

She added: I have some peripheral sight - barely any - and with what little sight I do have I was able to use to use to follow the lines on the track.

Libby wasnt born blind, and started losing her eyesight at the age of 9.

But theres currently no treatment for Stargardt, and eventually, the mother-of-one will lose her entire sight.

She continued: Im at the age where my sight should be stabilising but its still deteriorating.

Things will never go black, but I dont know yet exactly what I will be able to see.

Speaking to The Radio Times about her learning process on the ice rink, Live explained: Its been a learning process.

DON'T MISS

On the track I run with a guide runner and were attached all the time, but basically its like learning a different vocabulary to communicate.

Myself and my partner Mark Hanretty use touch and verbal communication.

Im not as bad as I thought I was going to be, but its not as easy as it looks.

Its a lot harder than I thought itd be, its very technical."

Moorfields Eye Hospital, part of the NHS Foundation Trust, says Stargardt disease is a rare inherited condition affecting one in 8,000 to 10,000 people.

It explains: In Stargardts the light-sensitive layer of cells in the macular region of the eye degenerate.

The macular is the area at the back of the eye which is responsible for the fine detailed vision necessary for activities such as watching TV and reading.

Symptoms of the condition include:

Moorfields Eye Hospital says UV blocking sunglasses can offer some protection for remaining vision, but the condition is currently untreatable.

It adds: A number of novel interventions are currently under investigation, including stem cell therapies. Stem cells are a special type of cell which, when put under the right conditions, can develop into many other types of cell including those found in the macular. It is hoped that new cells derived from stem cells can be grown in a laboratory to be transplanted into the eye to replace areas of dead or non-functioning cells. Stem cells can be sourced from a number of places including blood, bone marrow, umbilical cord and fertilized egg cells.

Researchers are involved in Europes first ongoing stem cell trial for Stargardts. More research will need to be undertaken in the future to determine to what extent stem cell therapy might help improve vision for people with Stargardts.

See the original post here:
Libby Clegg health: Dancing On Ice star is registered blind - what is her condition? - Express

Stem Cell Therapy Market is Anticipated to Attain a Market Value of US$XX by the End of 2017 2025 – Fusion Science Academy

Stem Cell Therapy Market Insights 2019, is a professional and in-depth study on the current state of the global Stem Cell Therapy industry with a focus on the Global market. The report provides key statistics on the market status of the Stem Cell Therapy manufacturers and is a valuable source of guidance and direction for companies and individuals interested in the industry. Overall, the report provides an in-depth insight of 2019-2025 global Stem Cell Therapy market covering all important parameters.

Request Sample Report @ https://www.tmrresearch.com/sample/sample?flag=B&rep_id=1787&source=atm

The key points of the Stem Cell Therapy Market report:

The report provides a basic overview of the Stem Cell Therapy industry including its definition, applications and manufacturing technology.

The report explores the international and Chinese major industry players in detail. In this part, the report presents the company profile, product specifications, capacity, production value, and 2019-2025 market shares for each company.

Through the statistical analysis, the report depicts the global total market of Stem Cell Therapy industry including capacity, production, production value, cost/profit, supply/demand and Chinese import/export.

The total market is further divided by company, by country, and by application/type for the competitive landscape analysis.

The report then estimates 2019-2025 market development trends of Stem Cell Therapy industry. Analysis of upstream raw materials, downstream demand, and current market dynamics is also carried out.

The report makes some important proposals for a new project of Stem Cell Therapy Industry before evaluating its feasibility.

Request For Discount On This Report @ https://www.tmrresearch.com/sample/sample?flag=D&rep_id=1787&source=atm

There are 3 key segments covered in this report: competitor segment, product type segment, end use/application segment.

For competitor segment, the report includes global key players of Stem Cell Therapy are included:

Key Trends

The key factors influencing the growth of the global stem cell therapy market are increasing funds in the development of new stem lines, the advent of advanced genomic procedures used in stem cell analysis, and greater emphasis on human embryonic stem cells. As the traditional organ transplantations are associated with limitations such as infection, rejection, and immunosuppression along with high reliance on organ donors, the demand for stem cell therapy is likely to soar. The growing deployment of stem cells in the treatment of wounds and damaged skin, scarring, and grafts is another prominent catalyst of the market.

On the contrary, inadequate infrastructural facilities coupled with ethical issues related to embryonic stem cells might impede the growth of the market. However, the ongoing research for the manipulation of stem cells from cord blood cells, bone marrow, and skin for the treatment of ailments including cardiovascular and diabetes will open up new doors for the advancement of the market.

Global Stem Cell Therapy Market: Market Potential

A number of new studies, research projects, and development of novel therapies have come forth in the global market for stem cell therapy. Several of these treatments are in the pipeline, while many others have received approvals by regulatory bodies.

In March 2017, Belgian biotech company TiGenix announced that its cardiac stem cell therapy, AlloCSC-01 has successfully reached its phase I/II with positive results. Subsequently, it has been approved by the U.S. FDA. If this therapy is well- received by the market, nearly 1.9 million AMI patients could be treated through this stem cell therapy.

Another significant development is the granting of a patent to Israel-based Kadimastem Ltd. for its novel stem-cell based technology to be used in the treatment of multiple sclerosis (MS) and other similar conditions of the nervous system. The companys technology used for producing supporting cells in the central nervous system, taken from human stem cells such as myelin-producing cells is also covered in the patent.

Global Stem Cell Therapy Market: Regional Outlook

The global market for stem cell therapy can be segmented into Asia Pacific, North America, Latin America, Europe, and the Middle East and Africa. North America emerged as the leading regional market, triggered by the rising incidence of chronic health conditions and government support. Europe also displays significant growth potential, as the benefits of this therapy are increasingly acknowledged.

Asia Pacific is slated for maximum growth, thanks to the massive patient pool, bulk of investments in stem cell therapy projects, and the increasing recognition of growth opportunities in countries such as China, Japan, and India by the leading market players.

Global Stem Cell Therapy Market: Competitive Analysis

Several firms are adopting strategies such as mergers and acquisitions, collaborations, and partnerships, apart from product development with a view to attain a strong foothold in the global market for stem cell therapy.

Some of the major companies operating in the global market for stem cell therapy are RTI Surgical, Inc., MEDIPOST Co., Ltd., Osiris Therapeutics, Inc., NuVasive, Inc., Pharmicell Co., Ltd., Anterogen Co., Ltd., JCR Pharmaceuticals Co., Ltd., and Holostem Terapie Avanzate S.r.l.

Customize This Report @ https://www.tmrresearch.com/sample/sample?flag=CR&rep_id=1787&source=atm

Reasons to Purchase this Report:

* Estimates 2019-2025 Stem Cell Therapy market development trends with the recent trends and SWOT analysis

* Market dynamics scenario, along with growth opportunities of the market in the years to come

* Market segmentation analysis including qualitative and quantitative research incorporating the impact of economic and policy aspects

* Regional and country level analysis integrating the demand and supply forces that are influencing the growth of the market.

* Competitive landscape involving the market share of major players, along with the new projects and strategies adopted by players in the past five years

* Comprehensive company profiles covering the product offerings, key financial information, recent developments, SWOT analysis, and strategies employed by the major market players

Read the rest here:
Stem Cell Therapy Market is Anticipated to Attain a Market Value of US$XX by the End of 2017 2025 - Fusion Science Academy